Fasiglifam as a new potential treatment option for patients with type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 18, 2013, Pages 2591-2600

  Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Fasiglifam; Free fatty acid receptor 1; G protein coupled receptor; Hypoglycaemia; TAK 875; Type 2 diabetes

Indexed keywords

C PEPTIDE; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PROINSULIN;

ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; CENTRAL AMERICA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; JAPAN; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORTH AMERICA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; BENZOFURANS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; SULFONES;

EID: 84887891741     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.851668     Document Type: Review

References (42)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
2. Sturm R. Stemming the global obesity epidemic: What can we learn from data about social and economic trends? Public Health 2008;122:739-46
3. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: Where do we go from here? Science 2003;299:853-5
4. BlonDe L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123(3 Suppl):S12-18
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12
6. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61
7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:540-59
8. Global guideline for type 2 diabetes. International Diabetes Federation Clinical Guidelines Task Force. Brussels: International Diabetes Federation, 2005. Available from: Http://www.idf.org/ guidelines/type-2-diabetes [Last accessed 22 June 2013]
9. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
10. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta, GA: 2011
11. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
12. Qaseem A, Humphrey LL, Sweet DE, et al. Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-31
13. Arai K, Matoba K, Hirao K, et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: Second report of a cross-sectional survey of 15,652 patients. Endocr J 2010;57:499-507
14. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 2003;26:1176-80
15. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303
16. Vlckova V, Cornelius V, Kasliwal R, et al. Hypoglycaemia with oral antidiabetic drugs: Results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Saf 2009;32:409-18
17. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: Quantification, validation, and utilization. Diabetes Care 1987;10:617-21
18. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs 2013;18:245-58
19. Pratley RE. Alogliptin: A new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009;10:503-12
20. Rayasam GV, Tulasi VK, Davis JA, Bansal VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007;11:661-71
21. Bailey CJ. Could FFAR1 assist insulin secretion in type 2 diabetes? Lancet 2012;379:1370-1
22. Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR) 40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012;55:2682-92
23. Negoro N, Sasaki S, Mikami S, et al. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010;1:290-4
24. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57:2280-7
25. Prentki M, Vischer S, Glennon MC, et al. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 1992;267:5802-10
26. Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 2002;173:73-80
27. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic b cells through GPR40. Nature 2003;422:173-6
28. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009;8:369-85
29. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signalling in rat islet b-cells: Mediation by PLC and L-Type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 2005;289:E670-7
30. Shapiro H, Shachar S, Sekler I, et al. Role of GPR40 in fatty acid action on the b cell line INS-1E. Biochem Biophys Res Commun 2005;335:97-104
31. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic b-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58:1067-76
32. Kebede M, Alquier T, Latour MG, et al. The fatty-Acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57:2432-7
33. Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1:245-58
34. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic b-cells. Diabetes Obes Metab 2010;12(Suppl 2):149-58
35. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: Results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2012;52:1007-16
36. Leifke E, Naik H, Wu J, et al. A multiple-Ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 2012;92:29-39
37. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: First clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 2012;14:271-8
38. Kaku K, Araki T, Yoshinaka R. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013;36:245-50
39. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1403-11
40. Kaku K. Fasiglifam (TAK-875), a novel GPR40 agonist reduces HbA1c in a 24-week clinical study-Phase III study results. Presented at the 56th Annual Meeting of the Japan Diabetes Society 2013
41. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
42. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-60